Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Insight Molecular Diagnostics (IMDX) Accumulated Depreciation & Amortization (2020 - 2023)

Insight Molecular Diagnostics (IMDX) has disclosed Accumulated Depreciation & Amortization for 4 consecutive years, with $1.3 million as the latest value for Q3 2023.

  • Quarterly Accumulated Depreciation & Amortization rose 232.48% to $1.3 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Sep 2023, up 232.48% year-over-year, with the annual reading at $1.5 million for FY2022, 87.5% up from the prior year.
  • Accumulated Depreciation & Amortization hit $1.3 million in Q3 2023 for Insight Molecular Diagnostics, up from $885000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $1.5 million in Q4 2022 to a low of -$2.4 million in Q2 2020.
  • Historically, Accumulated Depreciation & Amortization has averaged $167533.3 across 4 years, with a median of $327000.0 in 2021.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 17.43% in 2022 and later surged 232.48% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $313000.0 in 2020, then surged by 155.59% to $800000.0 in 2021, then surged by 87.5% to $1.5 million in 2022, then decreased by 13.33% to $1.3 million in 2023.
  • Business Quant data shows Accumulated Depreciation & Amortization for IMDX at $1.3 million in Q3 2023, $885000.0 in Q2 2023, and $450000.0 in Q1 2023.